A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Ubenimex (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms LIBERTY
- Sponsors Eiger BioPharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 12 May 2017 According to an Eiger BioPharmaceuticals media release, data anticipated in first quarter 2018 at JPM.
- 12 May 2017 Status changed from recruiting to active, no longer recruiting, as reported in an Eiger BioPharmaceuticals media release.